Last $75.80 USD
Change Today +0.55 / 0.73%
Volume 2.1M
BAX On Other Exchanges
New York
SIX Swiss Ex
As of 8:04 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/14 - $77.31
52 Week Low
10/2/13 - $62.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.

61,000 Employees
Last Reported Date: 02/21/14
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $687.7K
Corporate Vice President and President of Int...
Total Annual Compensation: $771.2K
Corporate Vice President and President of Bio...
Total Annual Compensation: $742.3K
Compensation as of Fiscal Year 2013.

baxter international inc (BAX) Key Developments

Baxter International Inc. Plans to Expand its Manufacturing Facility in Opelika, Alabama

Baxter International Inc. announced that it plans to expand its manufacturing facility in Opelika, Alabama, to help address the growing global demand for dialyzers, a critical component used in hemodialysis therapy (HD). Baxter will invest nearly $300 million in the Opelika site to add 230,000 square feet and several production lines. The company currently employs about 170 people at the facility, and anticipates it will begin the hiring process of the additional 200 workers in 2016 to support the expansion, which is when the first commercial production on the new lines is slated to begin.

Baxter Opens First State-of-the-Art Biologics Facility in Singapore

Baxter International Inc. announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite. The current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the full-length recombinant factor VIII (rFVIII) worldwide for the treatment of patients with hemophilia A. The second suite will initially process RIXUBIS [Coagulation Factor IX (Recombinant)], a recombinant factor IX (rFIX) protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company's investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval. The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of ADVATE. This allows the facility to process and supply ADVATE to the European Union, Iceland and Norway. The facility is the third location in the world supporting ADVATE processing, making this the only recombinant factor VIII treatment processed at three separate sites and providing unprecedented security of a triple-source capability.

FDA Approves Baxter International, Inc.'s FLEXBUMIN 5%

Baxter International Inc. announced that the United States Food and Drug Administration (FDA) has approved FLEXBUMIN(R) [Albumin (Human)], USP, 5% Solution. FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns and in patients undergoing cardiopulmonary bypass surgery. The FLEXBUMIN flexible, shatterproof container offers unique safety features for hospitals by eliminating risk of glass breakage and affords the ability to infuse without a vented administration set. In addition, FLEXBUMIN 5% solution provides efficiency features for healthcare professionals through its streamlined three-step administration process, lighter weight and reduced space requirements compared to glass containers of equal volume, making it more compatible with hospital inventory storage systems. FLEXBUMIN uses Baxter's GALAXY(R) flexible container, a proprietary multi-layer system that helps maintain albumin quality and allows the solution to be stored at room temperature. The GALAXY container, which employs barrier technology and a continuous aseptic filling process, has been used in the United States for more than 16 years to package pharmaceutical products. The flexible infusion system allows for simple administration steps with a non-vented administration set. Compared with glass bottles of equal volume, shipping containers for FLEXBUMIN 5% contain approximately 45% less packaging materials and empty containers are 95% lighter, resulting in less waste.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:US $75.80 USD +0.55

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,516 JPY +0.50
Covidien PLC $89.02 USD +0.23
Danone SA €52.94 EUR -0.47
Kimberly-Clark Corp $109.18 USD +0.61
Takeda Pharmaceutical Co Ltd ¥4,723 JPY +2.50
View Industry Companies

Industry Analysis


Industry Average

Valuation BAX Industry Range
Price/Earnings 21.2x
Price/Sales 2.5x
Price/Book 4.7x
Price/Cash Flow 20.9x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at